Ivermectin Naming Rights Means Big Profits for Big Pharma
Though the efficacy of Ivermectin as a prophylactic measure against
Covid-19 the Gain of Function Flu (manmade) is well documented, and has been known for some time, because Big Pharma cannot profit from the prescribing of Ivermectin, lies have been built up around Ivermectin and its use has been heavily lobbied against by the CDC, NIH, and WHO.
In order to profit from Ivermectin’s efficacy, but in order to actually make lots of money, Pfizer is attempting to bring to market Pfizermectin, actually currently referred to by Pfizer as PF-07321332, which apparently acts as protease inhibitor just like Ivermectin. Bastards.
“Another piece US anti-Ivermectin puzzle may have emerged. On Monday, Pfizer announced that it’s launching an accelerated Phase 2/3 trial for a COVID prophylactic pill designed to ward off COVID in those may have come in contact with the disease.
Coincidentally (or not), Pfizer’s drug shares at least one mechanism of action as Ivermectin – an anti-parasitic used in humans for decades, which functions as a protease inhibitor against Covid-19, which researchers speculate “could be the biophysical basis behind its antiviral efficiency.”
Lo and behold, Pfizer’s new drug – which some have jokingly dubbed “Pfizermectin,” is described by the pharmaceutical giant as a “potent protease inhibitor.””
Via Small Dead Animals.